Joyce EL, et al. - In this retrospective cohort study, researchers compared piperacillin/tazobactam (TZP) with cefepime (an alternative frequently used in intensive care units, with and without vancomycin) in terms of the risk of AKI when used to treat critically ill children. After exposure to vancomycin, TZP, and cefepime, alone or in combination, within 48 hours of admission, pediatric intensive care unit patients were examined for the risk of AKI. Increased odds of AKI in correlation with TZP use were shown by observational data in critically ill children. Some uncertainty regarding the nature of the link between TZP and AKI was created by a weaker, nonsignificant link between vancomycin plus TZP and AKI vs vancomycin plus cefepime. However, no link with AKI was shown by cefepime.